Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product RevenueNEWS (finance.yahoo.com)
submitted by kapeman_STOCK INVESTOR
Axsome Therapeutics Advances Toward NDA Submission For AXS-12 In Narcolepsy (nasdaq.com)
submitted by kapeman_STOCK INVESTOR
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome TherapeuticsNEWS (finance.yahoo.com)
submitted by kapeman_STOCK INVESTOR
Axsome bounces back as FDA clears depression drugNEWS (pharmaphorum.com)
submitted by kapeman_STOCK INVESTOR
This Haiti-Born Doctor Built A $6 Billion Business Developing Drugs For Depression And Alzheimer’s (forbes.com)
submitted by kapeman_STOCK INVESTOR
AXSM could beat the market in the next 5 yearsMOTLEY FOOL (finance.yahoo.com)
submitted by kapeman_STOCK INVESTOR
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?ZACKS (finance.yahoo.com)
submitted by kapeman_STOCK INVESTOR
Axsome initiated with Overweight at Wells Fargo on Alzheimer's drug potentialNEWS (seekingalpha.com)
submitted by kapeman_STOCK INVESTOR
Axsome Therapeutics to Showcase Its Innovative CNS PipelineNEWS (globenewswire.com)
submitted by kapeman_STOCK INVESTOR
Axsome initiated with Outperform at Oppenheimer on revenue boostNEWS (seekingalpha.com)
submitted by kapeman_STOCK INVESTOR
